# Bacteria-Based Vaccines for HIV and Other Infections > This patent describes using specially engineered bacteria, like Salmonella, to create vaccines that teach the body to fight off viruses like HIV by showing it specific parts of the virus on the bacteria's surface. - **Patent:** US 12734234 - **Original title:** Compositions and methods for preventing and treating virus infection - **Granted:** 2026 - **Status:** Active - **Times cited:** 0 - **Field:** biotech, pharmaceutical, infectious_diseases, vaccine_development ## What it does This patent describes a method for creating vaccine candidates using bacteria. Specifically, it focuses on HIV, where bacteria are engineered to express (display) parts of the HIV virus, called MPER-derived antigens, on their outer surfaces. This display uses a natural bacterial mechanism called Gram autotransporters. When these engineered bacteria are used to immunize mice, the mice produce antibodies in their blood and vaginal washes that can bind to the bacteria. Crucially, at least one of these bacterial candidates also causes the production of antibodies that can neutralize (stop) HIV activity. This approach includes using both killed whole bacteria and live *Salmonella* to deliver these antigens. ## What it does NOT cover - Vaccines that do not use bacteria as the primary delivery platform for antigens. - Vaccines that rely on traditional methods like inactivated viruses, attenuated viruses, viral vectors, or mRNA technology. - Vaccine candidates targeting parts of the HIV virus other than MPER-derived antigens. - Vaccines that present antigens internally within a cell rather than on the bacterial surface. - Bacterial vaccine platforms that do not utilize Gram autotransporters for surface antigen expression. ## The clever bit The novelty lies in using common bacteria, like *Salmonella*, as a living or killed 'display system' to present specific viral antigens, such as the MPER region of HIV, directly on their surface. This allows the immune system to recognize and respond to these viral parts in a way that could lead to protective immunity. ## Real-world examples 1. HIV vaccine research 2. Oral vaccine development 3. Bacterial vector vaccines 4. Mucosal immunity studies ## Why it matters This patent addresses the significant global challenge of developing an effective HIV vaccine. The proposed bacteria-based approach, particularly using *Salmonella*, offers the potential for an inexpensive and globally appropriate vaccine. Such a vaccine could be rapidly produced and deployed using existing technologies, which is critical for widespread access and impact in areas most affected by HIV. ## Frequently asked questions ### What does Bacteria-Based Vaccines for HIV and Other Infections cover? This patent describes using specially engineered bacteria, like Salmonella, to create vaccines that teach the body to fight off viruses like HIV by showing it specific parts of the virus on the bacteria's surface. ### When does this patent expire? This patent is expected to expire on September 15, 2046, when the invention enters the public domain. ### What problem does this patent solve? This patent addresses the significant global challenge of developing an effective HIV vaccine. The proposed bacteria-based approach, particularly using *Salmonella*, offers the potential for an inexpensive and globally appropriate vaccine. Such a vaccine could be rapidly produced and deployed using existing technologies, which is critical for widespread access and impact in areas most affected by HIV. ### What does this patent NOT cover? Vaccines that do not use bacteria as the primary delivery platform for antigens. **Full plain-English explainer:** https://patentbrief.org/patent/us/12734234/compositions-and-methods-for-preventing-and-treating-virus-infection **Original patent:** https://patents.google.com/patent/US12734234 --- _Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._ ## Related patents Semantically similar inventions in the PatentBrief corpus: - [How to Make Anthrax Vaccines That Survive Freezing](https://patentbrief.org/patent/us/10357559/luxturna-voretigene-neparvovec) — A method for protecting sensitive anthrax vaccines from damage during freezing and thawing by using specific sugars and additives during the drying process. - [Using Genetically Modified Viruses to Target and Treat Cancer](https://patentbrief.org/patent/us/9492534/yescarta-axicabtagene-ciloleucel) — A method for creating a modified vaccinia virus that safely hunts down and kills tumor cells while leaving healthy tissue alone. - [Boosting Anti-Infective Activity with Muramyldipeptides and Liposomes](https://patentbrief.org/patent/us/4522811/human-growth-hormone-protropin) — This patent describes a method to make anti-infective drugs called muramyldipeptides work better by injecting them separately but close in time with tiny fat bubbles called liposomes into an animal. - [Using Insect Cells to Create Antibodies for Human Diseases](https://patentbrief.org/patent/us/5397703/hepatitis-c-virus-genome-discovery) — A method for creating disease-fighting antibodies by using insect cells to display human proteins, which are then injected into animals to trigger an immune response. - [How an mRNA Vaccine Teaches Your Body to Fight Rabies](https://patentbrief.org/patent/us/12083190/rabies-vaccine) — This patent describes a method for creating an immune response against the rabies virus by injecting a specific messenger RNA molecule that instructs cells to produce a key rabies protein.